Accuray Receives 510(k) Clearance For New Radixact System - Quick Facts

(RTTNews) - Accuray Inc. (ARAY) announced it has received 510(k) clearance from the U.S. FDA for its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

"The Radixact System gives the radiation therapy team expanded capabilities across the widest range of patient cases, from the routine to the most complex, with precision, speed and efficient workflows," said Joshua Levine, CEO of Accuray.

The company will initiate commercial release of the Radixact System late in the first quarter of fiscal 2017.